SOF-SKN manufacturing begins to ensure clinical trial readi
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Noxopharm Ltd. has announced the commencement of SOF-SKN manufacturing to prepare for an upcoming clinical trial later this year. The manufacturing process is expected to take several weeks and includes rigorous quality control checks. This initiative aims to support preclinical investigations and further characterization of SOF-SKN's stability profile. Noxopharm is focusing on developing SOF-SKN for chronic inflammation caused by cutaneous lupus erythematosus and potentially other autoimmune diseases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference
- Noxopharm progresses US regulatory strategy
- New data shows SOF-SKN active ingredient efficacy
- Innovative collaboration further expands Sofra platform
Later from Noxopharm
- Quarterly Activities/Appendix 4C Cash Flow Report
- New study further validates Noxopharms cancer pipeline
- New preclinical data supports immuno-oncology approach
- Appendix 4E - Preliminary Financial Report
- Novel oligonucleotides data presented at Options Conference
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm